Gabapentin is an Efficacy Treatment for Facial Flushing and Erythema of Erythematotelangiectatic Rosacea: A Randomized Clinical noninferiority Trial

In this dataset, we have provided supplementary information for the study titled "Gabapentin is an Efficacy Treatment for Facial Flushing and Erythema of Erythematotelangiectatic Rosacea: A Randomized Clinical Noninferiority Trial." The supplementary materials include supplementary Figures and tables. A detailed description is provided below:
Supplementary Figure 1. Study flow diagram.
Supplementary Figure 2. The correlations between PSOI and VAS score improvement with CEA improvement in the gabapentin and carvedilol group at 12 weeks. The improvement in PSQI score (A) and VAS score for migraine (B) during gabapentin treatment was associated with the improvement in the CEA scores at 12 weeks. The improvement in PSQI score (C) and VAS score for migraine (D) during carvedilol treatment was no correlation with the improvement in the CEA scores at 12 weeks.
Supplementary Table 1. Baseline of demographic and clinical characteristics in patients with ETR.
Supplementary Table 2. Outcomes of anxiety and depression in gabapentin and carvedilol treatment.
Supplementary Table 3. Overview of TEAEs in the safety population
Supplementary Table 4. Clinician’s Erythema Assessment (CEA) scale
Supplementary Table 5. Patient’s Self-Assessment (PSA) scale